App Detecting Jaundice in Babies a Success in First Major Clinical Trial

A smartphone app that identifies severe jaundice in newborn babies by scanning their eyes could be a life-saver in areas that lack access to expensive screening devices, suggests a study co-authored by researchers at UCL (University College London) and the University of Ghana.

The app, called neoSCB, was developed by clinicians and engineers at UCL and was used to screen for jaundice in over 300 newborn babies in Ghana, following an initial pilot study on 37 newborns at University College London Hospital (UCLH) in 2020.

For the large-scale study, published in Paediatrics, the team tested over 300 babies with the app, which analyses images taken on a smartphone camera to quantify the yellowness of the white part of the eye (sclera) - a sign of neonatal jaundice. Analysing the yellowness of the eye just by looking is unreliable, and the neoSCB app can give early diagnosis of neonatal jaundice requiring treatment.

The study compared the effectiveness of the neoSCB app with conventional screening methods. Of the 336 babies tested by the app, 79 were severely jaundiced newborns, and the app correctly identified 74 of them. This is in line with the accuracy of the most common conventional screening method, a non-invasive device known as a transcutaneous bilirubinometer, which correctly identified 76.

The transcutaneous bilirubinometer works by measuring the yellow pigment under the newborn's skin to give a measure of jaundice levels. All screening results are then followed up by blood tests to determine the type of treatment required.

Dr Terence Leung (UCL Medical Physics & Biomedical Engineering) who developed the technology behind the app, said: "The study shows that the neoSCB app is as good as commercial devices currently recommended to screen for severely jaundiced newborns, but the app only requires a smartphone which costs less than a tenth of the commercial device. We hope that, once rolled out widely, our technology can be used to save the lives of newborns in parts of the world that lack access to expensive screening devices."

Study lead Dr Christabel Enweronu-Laryea (University of Ghana Medical School) said: "The neoSCB method was acceptable to mothers in urban and rural communities where the study was conducted. Mothers easily devised ways to keep the baby's eye open, most often by initiating breastfeeding."

Jaundice, where the skin and whites of the eye turn yellow, is common in newborns and is usually harmless. The yellowness is caused by a substance called bilirubin, which in severe cases can enter the brain, leading to death or disabilities such as hearing loss, neurological conditions such as athetoid cerebral palsy and developmental delays.

Every year severe jaundice causes about 114,000 newborn deaths and 178,000 cases of disability worldwide, despite it being a treatable condition. Most cases of neonatal jaundice occur in the first week after birth, and routine screening for early diagnosis in higher income countries has reduced the risks of severe complications.

Newborns in low- and middle-income countries are typically at a greater risk of severe jaundice, or neonatal hyperbilirubinemia, because of the lack of resources required for screening. A commercial transcutaneous bilirubinometer typically costs around £4,000 per device, and blood tests require a large amount of capacity. Additional factors such as a higher prevalence of home births and early postnatal discharge can contribute to fewer newborns going through screening.

Babies in sub-Saharan Africa are also at a greater risk because of a high prevalence of glucose-6-phosphate dehydrogenase (G6PD) deficiency, which is an inherited genetic disorder associated with an increased risk of haemolysis - where red blood cells break down at a faster rate than they are made - and hyperbilirubinemia.

Senior author Dr Judith Meek (UCLH) added: "This app has the potential to prevent death and disability worldwide in many different settings. It will reduce unnecessary hospital visits and potentially empower community health workers and parents to care for newborn babies safely."

In total, 724 newborns aged between 0 and 28 days were initially considered for the study. The 336 whose datasets were used for the paper had had no prior treatment for jaundice. Babies who were born at less than 35 weeks, were critically ill or had a very low birth weight were excluded from the final study. The app was tested with frontline healthcare workers and the babies’ mothers, who provided feedback on the usability of the app.

The study was supported by the Saving Lives at Birth consortium and the EPSRC UCL Centre for Doctoral Training in Intelligent Integrated Imaging in Healthcare.

Enweronu-Laryea C, Leung T, Outlaw F, Brako NO, Insaidoo G, Hagan-Seneadza NA, Ani-Amponsah M, Nixon-Hill M, Meek J.
Validating a Sclera-Based Smartphone Application for Screening Jaundiced Newborns in Ghana.
Pediatrics. 2022 Jun 3:e2021053600. doi: 10.1542/peds.2021-053600

Most Popular Now

Open Call HORIZON-MISS-2022-CANCER-01-04…

The overall goal of the Mission on Cancer[1] and the Europe's Beating Cancer Plan[2] includes a better quality of life for patients and their families living with, and after, cancer. Project...

Researchers Use AI to Predict Cancer Ris…

An artificial intelligence (AI) tool helps doctors predict the cancer risk in lung nodules seen on CT, according to a new study published in the journal Radiology. Pulmonary nodules appear as...

Insilico Medicine Raises $60 Million in …

Insilico Medicine, a clinical-stage end-to-end artificial intelligence (AI)-driven drug discovery company, announced today that it has completed a $60 million Series D financing from a syndicate of global investors with...

Speech Analysis App Predicts Worsening H…

A voice analysis app used by heart failure patients at home recognises fluid in the lungs three weeks before an unplanned hospitalisation or escalation in outpatient drug treatment. The late...

Siemens Healthineers and Penta Hospitals…

Penta Hospitals International, the largest multi-national hospital chain in Central and Eastern Europe, agreed a strategic partnership with Siemens Healthineers valued at over 30 million euros. Penta Hospitals International operates...

Screening for Diabetic Retinopathy Prove…

Both telemedicine and community screening for diabetic retinopathy (DR) in rural and urban settings are cost-effective in China, and telemedicine screening programs are more cost-effective, according to a study led...

KTU Researchers Investigate the Links Be…

In recent years Alzheimer's disease has been on the rise throughout the world and is rarely diagnosed at an early stage when it can still be effectively controlled. Using artificial...

Researchers Develop Smartphone-Powered M…

A University of Minnesota Twin Cities research team has developed a new microfluidic chip for diagnosing diseases that uses a minimal number of components and can be powered wirelessly by...

Philips' Future Health Index 2022 Report…

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the publication of its Future Health Index (FHI) 2022 report: 'Healthcare hits reset: Priorities shift as...

App Detecting Jaundice in Babies a Succe…

A smartphone app that identifies severe jaundice in newborn babies by scanning their eyes could be a life-saver in areas that lack access to expensive screening devices, suggests a study...

InterSystems Wins Data Driven Product of…

InterSystems, a provider of next-generation solutions for enterprise digital transformation to help customers solve the most critical data challenges, has announced it received the prestigious Data Driven Product of the...